EBITDA Summary of InnoPharmax Inc.

InnoPharmax Inc.'s latest annual EBITDA in 2023 was -62.12 Million TWD , up 33.49% from previous year.
InnoPharmax Inc.'s latest quarterly EBITDA in 2024 Q2 was -19.76 Million TWD , down -6.11% from previous quarter.
InnoPharmax Inc. reported an annual EBITDA of -88.73 Million TWD in 2022, down -13.26% from previous year.
InnoPharmax Inc. reported an annual EBITDA of -69.76 Million TWD in 2021, down -208.96% from previous year.
InnoPharmax Inc. reported a quarterly EBITDA of -19.76 Million TWD for 2024 Q2, down -6.11% from previous quarter.
InnoPharmax Inc. reported a quarterly EBITDA of -11.74 Million TWD for 2023 Q2, down 0.0% from previous quarter.

Annual EBITDA Chart of InnoPharmax Inc. (2023 - 2019)

Name	EBITDA	EBITDA Difference
Allied Biotech Corporation	204.79 Million TWD	130.333%
GeneFerm Biotechnology Co., Ltd.	231.09 Million TWD	126.881%
Easywell Biomedicals, Inc.	-85.5 Million TWD	27.346%
TTY Biopharm Company Limited	1.52 Billion TWD	104.075%
Synmosa Biopharma Corporation	1 Billion TWD	106.158%
Orient EuroPharma Co., Ltd.	582.93 Million TWD	110.656%
Center Laboratories, Inc.	-175.17 Million TWD	64.537%
Tien Liang BioTech Co., Ltd.	31.04 Million TWD	300.077%
Orient Pharma Co., Ltd.	172.39 Million TWD	136.034%
Johnson Chemical Pharmaceutical Works Co., Ltd.	126.67 Million TWD	149.038%
Excelsior Biopharma Inc.	-29.36 Million TWD	-111.516%
DV Biomed Co., Ltd.	407.64 Million TWD	115.239%
Foresee Pharmaceuticals Co., Ltd.	-912.16 Million TWD	93.19%
Handa Pharmaceuticals, Inc.	802.78 Million TWD	107.738%
UniPharma Co., Ltd.	-16.25 Million TWD	-282.183%
Anxo Pharmaceutical Co., Ltd.	131.31 Million TWD	147.308%
Alar Pharmaceuticals Inc.	394.52 Million TWD	115.746%
Winston Medical Supply Co., Ltd.	228.32 Million TWD	127.207%
Mercury Biopharmaceutical Corporation	-39.03 Million TWD	-59.143%
Bioray Biotech Co., Ltd	12.13 Million TWD	611.908%
TSH Biopharm Corporation Limited	99.35 Million TWD	162.526%